Cold Chain Biologic Labels Market to Triple by 2036
June 25, 2026 — Cold chain biologic temperature monitoring labels market projected to grow from $60M in 2026 to $155M by 2036 at 10% CAGR, driven by biologics demand and regulatory compliance.
Curated Health Wellness News
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
New Scholarship for Cancer Survivors Launches Nationwide
June 25, 2026 — Keith D'Agostino Scholarship for Cancer Survivors offers financial aid to undergraduate survivors nationwide. Apply by Jan 15, 2027 with an essay on resilience. Learn more at keithdagostino.org.
Medical Device Contract Manufacturing Market to Reach $330 Billion by 2036
June 25, 2026 — The medical device contract manufacturing market is set to grow from $93.8B to $330.35B by 2036 at 12.1% CAGR, driven by OEM outsourcing, regulatory demands, and tech innovation.
Vibrant Nutraceuticals Launches Allerpause Immune Blend for Fast Allergy Relief
June 25, 2026 — Vibrant Nutraceuticals launches Allerpause Immune Blend, a fast-acting, non-drowsy allergy supplement with EZClear quail egg protein. Available at vibrantnutra.com.
Vibrant Nutraceuticals Launches Stomach Pro+® Postbiotic Supplement
June 25, 2026 — Discover Stomach Pro+® from Vibrant Nutraceuticals, a postbiotic supplement with LJ88® that balances stomach acid, supports digestion, and inhibits H. pylori. Available at vibrantnutra.com.
SVAD Unveils New Halo Procedure Content for Radiant Skin
June 25, 2026 — Silicon Valley Aesthetic Dermatology announces new content on the Halo Procedure, a hybrid fractional laser that boosts collagen and rejuvenates skin. Learn about benefits for sun damage, wrinkles, and acne scars.
Why a Second Opinion Matters for All-on-Four Dental Implants
June 25, 2026 — Get a second opinion for all-on-four dental implants from Dr. Alex Rabinovich in San Francisco. Learn why it matters for your smile and wallet.
$1,000 Scholarship for Future Doctors Focused on Health Equity
June 25, 2026 — Dr. Valinda Nwadike Scholarship offers $1,000 for undergraduate students pursuing healthcare careers, focusing on health disparities. Apply by Jan 15, 2027. No transcripts needed.
Ottobock Appoints Dr. Katarzyna Mazur-Hofsaess to Management Board
June 24, 2026 — Ottobock appoints Dr. Katarzyna Mazur-Hofsaess to its Management Board, succeeding Stefan Heidenreich. Learn about her expertise in medical technology and healthcare.
Eckert & Ziegler AGM Approves Higher Dividend for 2025
June 24, 2026 — Eckert & Ziegler SE AGM approves higher dividend of EUR 0.22 per share for 2025, up from EUR 0.17. Learn about the company's isotope components and radiopharmaceutical services.
Eckert & Ziegler AGM Approves Higher Dividend of EUR 0.22
June 24, 2026 — Eckert & Ziegler SE AGM approves higher dividend of EUR 0.22 per share for 2025, up from EUR 0.17. Key highlights and impact on nuclear medicine.
VERAXA Biotech Expands Lab in Heidelberg to Boost Cancer Pipeline
June 24, 2026 — VERAXA Biotech expands its Heidelberg lab to advance BiTAC cancer therapies. Learn about the company's pipeline and growth plans for next-generation oncology treatments.
LakeShore Biopharma Goes Private in Merger with Oceanpine
June 24, 2026 — LakeShore Biopharma completes going-private merger with Oceanpine Skyline, delisting from OTC markets. Shareholders receive $0.066 per share. The biopharmaceutical company focuses on vaccines and therapeutics using PIKA® technology.
VERAXA Biotech Reports Promising BiTAC-ADC Data for Targeted Cancer Therapy
June 24, 2026 — VERAXA Biotech (VRXA) announces new in vitro data for BiTAC-ADC platform, showing selective cancer cell destruction. Company to seek partnerships at BIO 2026.
Cancer Nanomedicine Gets a Boost: Onco-Innovations' ONC010 Advances
June 24, 2026 — Onco-Innovations (ONCO, ONNVF) advances cancer nanomedicine with ONC010, a PNKP inhibitor using polymer nanodelivery for improved tumor targeting and tolerability.
New Enzyme Discovery Could Block Brain Cancer Metastases
June 24, 2026 — Researchers discover a molecular pathway critical to brain cancer metastasis, potentially changing treatment. CNS Pharmaceuticals also advances therapies. Learn more.
Next-Gen DNA Repair Inhibitors Poised to Capture Billions in Cancer Market
June 24, 2026 — Onco-Innovations advances ONC010, a nanoparticle PNKP inhibitor, in the growing DDR inhibitor market. Learn how this precision medicine approach targets cancer DNA repair, with the market projected to hit $750B by 2030.
Quantum BioPharma’s Lucid-MS Aims to Halt Multiple Sclerosis
June 24, 2026 — Quantum BioPharma's Lucid-MS enters phase 2 trials to halt multiple sclerosis progression. Learn how this novel therapy targets myelin repair, offering hope for millions living with MS.
Quantum BioPharma Advances Lucid-MS for Multiple Sclerosis
June 24, 2026 — Quantum BioPharma advances Lucid-MS, a first-in-class drug for multiple sclerosis that protects myelin. Phase 2 trial preparation underway after successful safety studies.
Onco-Innovations Targets $7B DDR Market with Novel PNKP Inhibitor
June 24, 2026 — Onco-Innovations advances ONC010™, a nanoparticle PNKP inhibitor, targeting the $7B DDR oncology market. Preclinical success in colorectal cancer models and strategic partnerships highlight its potential. Learn more.